Finch Therapeutics Group Inc (FNCH) Return on Equity ROE from the second quarter 2024 to second quarter 2023 and annually, average high and low, overall ranking from Jun 30 2024 to Jun 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Finch Therapeutics Group Inc   (NASDAQ: FNCH)

Finch Therapeutics Group Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Finch Therapeutics Group Inc in the second quarter 2024?
Finch Therapeutics Group Inc recorded a cumulative net loss of $-14 million during 12 months ending in the second quarter 2024, resulting in a negative return on equity (ROE) of -69.14%.

Within the Biotechnology & Pharmaceuticals industry 65 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2024 from 0 to 3273.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter
Y / Y Equity Change -49.02 % -44.89 % -76.09 % -78.64 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -14 -16 -75 -99 -137
Return On Equity (TTM) -69.14 % -68.11 % -269.05 % -214.66 % -195.94 %
FNCH's Total Ranking # 3273 # 0 # 0 # 3766 # 3618
Equity (TTM) in Millions 14 19 23 26 28
Seq. Equity Change -25.31 % -16.81 % -11.34 % -7.46 % -19.25 %
Seq. Net Income Change - - - - -

Back to FNCH Management Effectiveness >> FNCH's 5 Years Annual ROE >> Compare FNCH ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 66
Sector # 476
Overall # 3273

Return On Equity Statistics
High Average Low
-26.15 %
-110.21 %
-272.96 %
(Dec 31 2021)   (Dec 31 2023)





FNCH Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021

Total Equity in Millions 23 96 202 0 0
Y / Y Equity Change -76.09 % -52.67 % - - -
Net Income in Millions -75 -115 -58 0 0
Y / Y Net Income Change - - - - -
Return On Equity -326.64 % -119.78 % -28.76 % - -

Back to FNCH Management Effectiveness >> FNCH's 5 Years Annual ROE >> Compare FNCH ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
FNCH's' Return on Equity at Yahoo Finance
FNCH's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for FNCH's Competitors
Subscribers only: Roe for Finch Therapeutics Group Inc 's Suppliers
Subscribers only: Return On Equity for FNCH's Customers




Companies with similar Return On Equity at Jun 30 2024, within Healthcare Sector ROE

Date modified: 2026-09-26T07:39:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.